Vertex Reports First Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Vertex Pharma (VRTX) Tops Q1 EPS by 14c, Misses on Revenue; Offers FY26 Revenue Guidance
May 4, 2026 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.47, $0.14 better than the analyst estimate of $4.33. Revenue for the quarter came in at $2.99 billion versus the consensus estimate of $3.03 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of... More
